Reduces elevated serum total and low-density lipoprotein (LDL) cholesterol. ANDA 77277, held by Impax Labs. Colestipol Hydrochloride.
As of Nov 16, 2026, ANDA 77277 (Colestipol Hydrochloride), held by Impax Labs, was first approved by FDA on May 2, 2006, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride for oral suspension is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [LDL] cholesterol) who do not respond adequately to diet. Generally, colestipol hydrochloride for oral suspension has no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 2, 2006 | Original application | Approved |
| Colestipol Hydrochloride5GM/SCOOPFUL · granule;oral | Colestipol Hydrochloride | Discontinued |
| Colestipol Hydrochloride5GM/PACKET · granule;oral | Colestipol Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters